Through a prospective, randomized, controlled single-center trial, we compare the efficacy and recurrence rates of intravitreal injection of ranibizumab (IVR) versus laser therapy for the Zone II treatment-requiring retinopathy of prematurity and found IVR might not be suitable as a single-dose monotherapy for this disease.